IRIS UniCatt

Hohaus, Stefan
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.969
EU - Europa 7.406
AS - Asia 6.828
SA - Sud America 1.196
Continente sconosciuto - Info sul continente non disponibili 337
AF - Africa 184
OC - Oceania 31
Totale 25.951
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.633
SG - Singapore 2.921
DE - Germania 2.289
CN - Cina 1.713
SE - Svezia 1.110
BR - Brasile 973
IT - Italia 915
VN - Vietnam 819
PL - Polonia 727
FR - Francia 570
UA - Ucraina 458
GB - Regno Unito 350
IN - India 283
FI - Finlandia 260
IE - Irlanda 249
BD - Bangladesh 187
ID - Indonesia 176
CA - Canada 170
JP - Giappone 169
RU - Federazione Russa 130
HK - Hong Kong 126
TR - Turchia 90
MX - Messico 85
AR - Argentina 66
NL - Olanda 58
IQ - Iraq 56
ZA - Sudafrica 46
PK - Pakistan 45
ES - Italia 41
AT - Austria 40
CO - Colombia 39
BE - Belgio 34
EC - Ecuador 34
CI - Costa d'Avorio 32
VE - Venezuela 28
AU - Australia 27
CZ - Repubblica Ceca 27
KR - Corea 27
MA - Marocco 25
IR - Iran 24
CH - Svizzera 23
LT - Lituania 23
UZ - Uzbekistan 21
AE - Emirati Arabi Uniti 20
SA - Arabia Saudita 20
KE - Kenya 19
PY - Paraguay 18
IL - Israele 16
CL - Cile 14
MY - Malesia 14
CR - Costa Rica 13
EG - Egitto 13
GR - Grecia 13
HN - Honduras 13
RO - Romania 13
TN - Tunisia 13
JM - Giamaica 12
JO - Giordania 12
PE - Perù 12
PH - Filippine 12
AZ - Azerbaigian 11
NP - Nepal 10
LV - Lettonia 9
BG - Bulgaria 8
DZ - Algeria 8
ET - Etiopia 8
KZ - Kazakistan 8
PT - Portogallo 8
NO - Norvegia 7
AL - Albania 6
DK - Danimarca 6
GT - Guatemala 6
UY - Uruguay 6
XK - ???statistics.table.value.countryCode.XK??? 6
DO - Repubblica Dominicana 5
GE - Georgia 5
HU - Ungheria 5
NI - Nicaragua 5
OM - Oman 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
AM - Armenia 4
BO - Bolivia 4
BY - Bielorussia 4
CG - Congo 4
EU - Europa 4
HR - Croazia 4
LY - Libia 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
BZ - Belize 3
CU - Cuba 3
IS - Islanda 3
KW - Kuwait 3
LB - Libano 3
PS - Palestinian Territory 3
SN - Senegal 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
Totale 25.572
Salva come PNG Salva come JPEG
Città #
Singapore 1.627
Chandler 1.040
Ashburn 1.016
San Jose 913
Warsaw 694
Jacksonville 341
Beijing 305
Munich 254
Los Angeles 245
Dublin 240
Ho Chi Minh City 233
San Mateo 224
Nanjing 223
Hanoi 215
New York 214
Houston 207
Ann Arbor 201
Fairfield 200
Woodbridge 195
Dearborn 193
Wilmington 185
Lauterbourg 177
Rome 171
Milan 160
Jakarta 154
Tokyo 143
Hefei 134
Cambridge 127
Helsinki 126
Nürnberg 122
Dallas 120
The Dalles 119
Chicago 116
Hong Kong 114
Seattle 113
Frankfurt am Main 107
Cattolica 98
Boston 89
Bremen 88
Santa Clara 88
Nanchang 85
Moscow 84
Buffalo 80
Redmond 77
São Paulo 74
Lawrence 72
Redwood City 68
Council Bluffs 61
St Louis 59
Hyderabad 58
Marseille 58
Princeton 58
London 55
Kunming 54
Shanghai 48
Lancaster 47
Orem 47
Boardman 46
Da Nang 46
Montreal 43
Toronto 43
Guangzhou 42
Haiphong 42
Izmir 40
Kent 38
Tianjin 38
Atlanta 37
Brooklyn 37
Phoenix 36
Norwalk 35
Hangzhou 34
Nuremberg 34
Abidjan 32
Mexico City 32
Hebei 31
Brussels 30
Mountain View 29
Shenyang 29
Zhengzhou 29
Jiaxing 28
Rio de Janeiro 27
Changsha 26
Seoul 26
Belo Horizonte 25
Auburn Hills 24
Denver 24
Fremont 24
Johannesburg 24
Leawood 23
Tukwila 23
Amsterdam 22
Baghdad 22
Chennai 22
Paris 22
Stockholm 22
Turku 21
University Park 21
Poplar 20
Las Vegas 19
Nairobi 19
Totale 13.703
Salva come PNG Salva come JPEG
Nome #
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 437
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 366
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy 355
Fanconi anemia gene variants in therapy-related myeloid neoplasms 332
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization 331
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 305
Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients 304
THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA 300
PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma 294
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker 284
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies 251
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis 243
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies 240
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 240
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 237
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. 237
Italian real-life experience with brentuximab vedotin: Results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 233
Anemia in Diffuse Large B cell Non-Hodgkin Lymphoma: The Role of IL-6, Hepcidin and Erythropoietin 224
Enhancing lymphoma diagnosis on core needle biopsies: Integrating immunohistochemistry with flow cytometry 204
Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms : Long-Term Experience. 204
Why methylation is not a marker predictive of response to hypomethylating agents 204
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma 203
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 200
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 195
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance 195
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. 194
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 194
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 194
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 194
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 194
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 191
Iron in Hodgkin's lymphoma 189
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 188
Epigenetic changes in therapy-related MDS/AML 187
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 187
Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance 185
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas 184
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 184
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 178
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 178
Clonal evolution in therapy-related neoplasms 178
Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment 178
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 177
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 177
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine 175
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 172
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 171
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. 171
Primary multifocal lymphoma of peripheral nervous system: Case report and review of the literature 166
Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience 165
Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). 163
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference 163
Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances 163
Intravascular large B-cell lymphoma presenting as slowly progressive paraparesis with normal MRI features 161
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. 161
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma 159
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 158
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. 158
PU.1 and CEBPA expression in acute myeloid leukemia. 158
PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma 158
Intravascular large-B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. 157
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. 157
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication 157
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. 157
FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET) 157
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference 157
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. 156
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 156
A T cell lymphoblastic lymphoma with mucormycosis as unusual etiology of acute cerebral ischemia 156
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 154
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 153
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 152
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. 152
Dural MALT Lymphoma Detected by 11C-Methionine PET/CT 151
Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden 150
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 150
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 150
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma 149
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 149
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 149
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 149
The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL) 146
Small lymphocytic lymphoma in a patient with Fabry disease 144
Granulocyte transfusions as adjunctive treatment of invasive fungal diseases in neutropenic patients 144
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 142
Outcome of therapy-related myeloid neoplasms treated with azacitidine 142
Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma 142
May we routinely spare hippocampal region in primary central nervous system lymphoma during whole brain radiotherapy? 141
Primary pancreatic lymphoma in a patient with maturity onset diabetes of the young type 3 141
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 141
Mantle cell lymphoma relapsing at the lymphedematous arm 140
Muscle Recurrence of a Primarily Nodal Follicular Lymphoma Studied by Contrast-Enhanced 18F-FDG PET/CT 140
Prognostic factors in hodgkin lymphoma 139
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 139
Desensitization to thalidomide in a patient with multiple myeloma 136
Negative prognostic value of glutathione s-transferase (gstm1 and gstt1) deletions in adult acute myeloid leukemia. 136
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 136
Small lymphocytic lymphoma in a patient with Fabry disease 135
Clinical and prognostic features of lymphomas arising in the head and neck region: Our experience of preferential association of different histotypes with various sites of origin in ninety patients 135
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population 135
Totale 18.643
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.142 0 111 20 53 85 36 38 206 64 102 208 219
2022/20232.860 385 396 203 502 180 351 138 230 302 49 84 40
2023/20241.286 56 380 40 63 38 202 50 87 11 39 150 170
2024/20253.362 98 114 245 156 291 117 227 167 452 285 673 537
2025/20269.203 1.163 282 518 867 1.596 541 1.634 565 657 731 378 271
2026/2027996 372 624 0 0 0 0 0 0 0 0 0 0
Totale 25.951